Dr. Evans' practice is dedicated to the management of patients with urologic malignancies. He works with medical oncologists and radiation oncologists to provide multimodal approaches to cancer therapy. His surgical expertise includes robotic assisted laparoscopic radical prostatectomy with nerve sparing, complex renal surgery to include partial nephrectomy and vena cava thrombectomy, cystectomy with extended pelvic lymph node dissection and urinary diversion with orthotopic neobladders. Dr. Evans also has expertise in treating patients with metastatic testicular cancer and performing retroperitoneal lymph node dissection in post chemotherapy patients.
Dr. Evans' research laboratory focuses on prostate cancer; specifically, mechanisms signaling the androgen receptor to activate prostate cancer growth and progression following castration. His laboratory has developed models to study this and has identified novel mechanisms that activate the androgen receptor. His laboratory work has tested new agents and brought them from bench studies to animal models to clinical trials.
Dr. Evans' philosophy of care is to fully assess the patient's medical condition including how it relates to family and social circumstances, educate the patient fully about their disease process and include the patient in the decision making process that best suits the outcomes they seek. In each case he looks for opportunity to enroll them in any new therapies or clinical trials that may be available and pertinent.
B.A., University of Vermont, Burlington, Vermont, 1981
University of California, San Francisco, San Francisco, California, 1991-95
University of Texas, Anderson Cancer Center, Houston, Texas, 1995-97
American College of Surgeons, 2000
National Board of Medical Examiners, 1987
American Association for the Advancement of Science
American Association of Genitourinary Surgeons
American College of Surgeons
American Society of Clinical Oncology
American Urology Association
Association of Military Surgeons of the United States
European Association of Urology
Society for Basic Urologic Research
Society of Government Urologists
Society of Urologic Oncology
Southwest Oncology Group
Uniformed Services University
Honors and Awards:
Western Section AUA nominee for the Gold Cystoscope Award, 2005
1st Prize, Joseph F. McCarthy Essay Contest of the American Urological Association, 2003
Finalist, California Cancer Research Program Gerald P. Murphy Award, 2001
Third Place Award for Basic Science, University of California, Davis Cancer Center Symposium, 1998
Mortar Board Honor Society, 1998
Honorable Mention, AUA Circon/ACMI Essay Contest, Laboratory Research, 1996
Recipient NIH Travel Award Grant, Keystone Symposia on Molecular and Cellular Biology "Breast and Prostate Cancer: Basic Mechanisms", 1996
First Place Award for Basic Science, Society for University Urology Residents, National Chief Resident Meeting, 1995
Recipient, American Association for Cancer Research Young Investigator Award, "Basic and Clinical Aspects of Prostate Cancer", 1994
Northern California Urology Residents' Competition, First Place Award for Basic Science, 1994
Northern California Urology Residents' Competition, Second Place Award for Basic Science, 1993
Recipient, American Association for Cancer Research/National Cancer Institute Travel Grant. Molecular Biology Workshop, Aspen, CO, 1993
Northern California Urology Residents' Competition, Second Place Award for Basic Science, 1992
Northern California Urology Residents' Competition, First Place Award for Basic Science, 1991
Recipient, Army Commendation Medal, 1990
Finalist, Army Science Conference Competition, 1990
Select Recent Publications:
Nadiminty N, Tummala R, Lou W, Zhu Y, Zhang J, Chen X, eVere White RW, Kung HJ, Evans CP, Gao AC. MicroRNA let-7c suppresses androgen receptor expression and activity via regulation of Myc expression in prostate cancer cells. J Biol Chem. 2012 Jan 6;287(2):1527-37. Epub 2011 Nov 28.
Keegan KA, Dall'era MA, Durbin-Johnson B, Evans CP. Active surveillance for prostate cancer compared with immediate treatment: An economic analysis. Cancer. 2011 Dec 16. doi: 10.1002/cncr.26688. [Epub ahead of print]
Eastham JA, Evans CP, Zietman A. What is the optimal management of high risk, clinically localized prostate cancer? Urol Oncol. 2010 Sep-Oct;28(5):557-67.
Yang JC, Bai L, Yap S, Gao AC, Kung HJ, Evans CP. Effect of the specific Src family kinase inhibitor saracatinib on osteolytic lesions using the PC-3 bone model.Mol Cancer Ther . 2010 Jun;9(6):1629-37. Epub 2010 May 18.
Yang, J.C., Busby, J.E., OK, J., Borowsky, A.D., Kung, H-J., Evans, C.P. Aberrant Activation of Androgen Receptor in a New Neuropeptide-Autocrine Model of Androgen-Insensitive Prostate Cancer. Cancer Res. 69: 151-60. 2009.
Feng S., Tang Q., Sun M., Chun J.Y., Evans C.P., Gao A.C. Mol Cancer Therapy. Interleukin-6 Increases Prostate Cancer Cells Resistance to Bicalutamide Via TIF2. 8: 665-71. 2009.
Lara, P.N. Jr., Longmate, J, Evans, C.P., Quinn, D.I., Twardowski, P., Chatta, G, Posadas, E, Stadler, W., Gandara, D.R. A Phase II Trial of the Src-Kinase Inhibitor AZD0530 in Patients with Advanced Castration-Resistant Prostate Cancer: A California Cancer Consortium Study. Anti-Cancer Drugs. 20: 179-84. 2009.
Ramirez, M.L., Nelson, E.C., deVere White, R.W., Lara, P.N., Evans, C.P. Current Applications for Prostate-Specific Antigen Doubling Time. Eur Urol. Aug; 54(2): 291-302. 2008.
Chang Y-M, Bai L, Yang J.C., Kung H-J, Evans C.P. Src Family Kinase Oncogenic Potential and Pathways in Prostate Cancer As Revealed By AZD0530. Oncogene. Nov 6; 27(49): 6365-75. 2008.
Chang Y-M., Kung H-J., Evans C.P. Non-Receptor Tyrosine Kinases in Prostate Cancer. Neoplasia. 9(2): 90-100. 2007.
Cambio A.J., Ellison L.M., Chamie K., deVere White R.W., and Evans C.P. Cost-Benefit and Outcome Analysis: Effect of Prostate Biopsy Under-Grading. Urology. 69(6) 1152-6.
Shi XB, Xui L, Yang JC, MA A, Zhao J, Ma X, Tepper CG, Evans CP, Kung HJ, deVere White R. An Androgen-Regulated miRNA Suppresses Bak1 Expression and Induces Androgen-Independent Growth of Prostate Cancer Cells. PNAS 104: 19983-8. 2007.
Nelson E.C., Cambio A.J., Yang J.C., Lara P., and Evans C.P. Biologic Agents as Adjunctive Therapy for Prostate Cancer: A Rationale for Use with Androgen Deprivation. Nature Clinical Practice Urology. 4(2): 82-94. 2007.